| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.571 | 0.017 | 0.592 | 5 Hydroxytryptamine release stimulant | 0.571 0.018 DBMET03517 0.286 0.074 DBMET03518 0.571 0.018 DBMET03519 0.496 0.028 DBMET03522 0.592 0.015 DBMET03520 0.495 0.028 DBMET03521 | DBMET03520 | |
| 0.547 | 0.004 | 0.562 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.545 0.005 DBMET03517 0.506 0.007 DBMET03518 0.557 0.004 DBMET03519 0.529 0.005 DBMET03522 0.516 0.006 DBMET03520 0.562 0.004 DBMET03521 | DBMET03521 | |
| 0.534 | 0.003 | 0.603 | Poly(ADP-ribose) polymerase inhibitor | 0.543 0.003 DBMET03517 0.431 0.004 DBMET03518 0.603 0.003 DBMET03519 0.433 0.004 DBMET03522 0.456 0.004 DBMET03520 0.509 0.003 DBMET03521 | DBMET03519 | |
| 0.525 | 0.005 | 0.601 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.536 0.005 DBMET03517 0.417 0.014 DBMET03518 0.601 0.004 DBMET03519 0.491 0.007 DBMET03522 0.481 0.008 DBMET03520 0.581 0.005 DBMET03521 | DBMET03519 | |
| 0.506 | 0.006 | 0.506 | 5 Hydroxytryptamine 2 antagonist | 0.369 0.011 DBMET03517 0.163 0.04 DBMET03518 0.341 0.013 DBMET03519 0.168 0.038 DBMET03522 0.479 0.007 DBMET03520 0.453 0.008 DBMET03521 | ||
| 0.494 | 0.003 | 0.557 | Poly(ADP-ribose) polymerase 1 inhibitor | 0.503 0.003 DBMET03517 0.399 0.004 DBMET03518 0.557 0.003 DBMET03519 0.394 0.004 DBMET03522 0.413 0.004 DBMET03520 0.464 0.003 DBMET03521 | DBMET03519 | |
| 0.488 | 0.005 | 0.488 | 5 Hydroxytryptamine 2A antagonist | 0.359 0.008 DBMET03517 0.165 0.025 DBMET03518 0.316 0.01 DBMET03519 0.119 0.038 DBMET03522 0.448 0.005 DBMET03520 0.416 0.006 DBMET03521 | ||
| 0.474 | 0.008 | 0.562 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.486 0.007 DBMET03517 0.37 0.023 DBMET03518 0.562 0.005 DBMET03519 0.441 0.011 DBMET03522 0.47 0.008 DBMET03520 0.526 0.005 DBMET03521 | DBMET03519 | |
| 0.497 | 0.035 | 0.536 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.455 0.058 DBMET03517 0.364 0.136 DBMET03518 0.515 0.027 DBMET03519 0.536 0.02 DBMET03522 0.415 0.087 DBMET03520 0.422 0.082 DBMET03521 | DBMET03522 | |
| 0.452 | 0.016 | 0.598 | Anticonvulsant | 0.598 0.007 DBMET03517 0.379 0.024 DBMET03519 0.335 0.032 DBMET03522 0.51 0.012 DBMET03520 0.443 0.017 DBMET03521 | DBMET03517 | |
| 0.438 | 0.003 | 0.597 | Poly(ADP-ribose) polymerase 2 inhibitor | 0.415 0.003 DBMET03517 0.229 0.004 DBMET03518 0.597 0.003 DBMET03519 0.294 0.004 DBMET03522 0.34 0.004 DBMET03520 0.438 0.003 DBMET03521 | DBMET03519 | |
| 0.47 | 0.041 | 0.487 | Calcium channel L-type activator | 0.42 0.068 DBMET03517 0.349 0.118 DBMET03518 0.458 0.047 DBMET03519 0.487 0.033 DBMET03522 0.361 0.109 DBMET03520 0.288 0.168 DBMET03521 | DBMET03522 | |
| 0.413 | 0.005 | 0.413 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.369 0.009 DBMET03517 0.303 0.024 DBMET03518 0.379 0.008 DBMET03519 0.303 0.024 DBMET03522 0.277 0.039 DBMET03520 0.332 0.015 DBMET03521 | ||
| 0.377 | 0.003 | 0.4 | MAP-kinase-activated kinase inhibitor | 0.395 0.003 DBMET03517 0.333 0.004 DBMET03518 0.4 0.003 DBMET03519 0.366 0.003 DBMET03522 0.213 0.005 DBMET03520 0.318 0.004 DBMET03521 | DBMET03519 | |
| 0.383 | 0.012 | 0.498 | Protein kinase C nu inhibitor | 0.417 0.008 DBMET03517 0.272 0.03 DBMET03518 0.498 0.005 DBMET03519 0.384 0.012 DBMET03522 0.299 0.024 DBMET03520 0.436 0.007 DBMET03521 | DBMET03519 | |
| 0.359 | 0.006 | 0.359 | 5 Hydroxytryptamine agonist | 0.317 0.008 DBMET03517 0.093 0.036 DBMET03518 0.195 0.015 DBMET03519 0.149 0.022 DBMET03520 0.21 0.013 DBMET03521 | ||
| 0.359 | 0.009 | 0.394 | MAP-kinase-activated kinase 5 inhibitor | 0.355 0.01 DBMET03517 0.304 0.028 DBMET03518 0.394 0.005 DBMET03519 0.337 0.014 DBMET03522 0.311 0.024 DBMET03520 0.387 0.006 DBMET03521 | DBMET03519 | |
| 0.354 | 0.005 | 0.563 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.441 0.005 DBMET03517 0.223 0.011 DBMET03518 0.563 0.004 DBMET03519 0.286 0.008 DBMET03522 0.304 0.007 DBMET03520 0.3 0.007 DBMET03521 | DBMET03519 | |
| 0.365 | 0.024 | 0.55 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.376 0.022 DBMET03517 0.262 0.053 DBMET03518 0.55 0.006 DBMET03519 0.377 0.022 DBMET03522 0.405 0.017 DBMET03520 0.51 0.008 DBMET03521 | DBMET03519 | |
| 0.343 | 0.003 | 0.362 | MAP-kinase-activated kinase 2 inhibitor | 0.36 0.003 DBMET03517 0.302 0.004 DBMET03518 0.362 0.003 DBMET03519 0.333 0.003 DBMET03522 0.192 0.005 DBMET03520 0.282 0.004 DBMET03521 | DBMET03519 | |
| 0.361 | 0.023 | 0.387 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.348 0.025 DBMET03517 0.194 0.095 DBMET03518 0.387 0.017 DBMET03519 0.242 0.065 DBMET03522 0.261 0.055 DBMET03520 0.259 0.056 DBMET03521 | DBMET03519 | |
| 0.342 | 0.015 | 0.441 | 5 Hydroxytryptamine antagonist | 0.235 0.027 DBMET03517 0.26 0.024 DBMET03519 0.441 0.009 DBMET03520 0.42 0.01 DBMET03521 | DBMET03520 | |
| 0.386 | 0.06 | 0.436 | Vasodilator, peripheral | 0.191 0.187 DBMET03517 0.436 0.044 DBMET03522 | DBMET03522 | |
| 0.329 | 0.003 | 0.329 | 5 Hydroxytryptamine 2 agonist | 0.28 0.003 DBMET03517 0.078 0.016 DBMET03518 0.156 0.005 DBMET03519 0.056 0.032 DBMET03522 0.112 0.008 DBMET03520 0.255 0.004 DBMET03521 | ||
| 0.33 | 0.008 | 0.345 | 5 Hydroxytryptamine 2C antagonist | 0.246 0.013 DBMET03517 0.094 0.049 DBMET03518 0.213 0.016 DBMET03519 0.088 0.054 DBMET03522 0.345 0.007 DBMET03520 0.321 0.008 DBMET03521 | DBMET03520 | |
| 0.323 | 0.003 | 0.325 | MAP3K9 inhibitor | 0.317 0.003 DBMET03517 0.296 0.004 DBMET03518 0.325 0.003 DBMET03519 0.319 0.003 DBMET03522 0.253 0.005 DBMET03520 0.311 0.003 DBMET03521 | DBMET03519 | |
| 0.307 | 0.005 | 0.369 | Protein kinase C mu inhibitor | 0.326 0.005 DBMET03517 0.241 0.008 DBMET03518 0.369 0.004 DBMET03519 0.283 0.005 DBMET03522 0.227 0.009 DBMET03520 0.354 0.004 DBMET03521 | DBMET03519 | |
| 0.306 | 0.005 | 0.403 | Check point kinase 1 inhibitor | 0.366 0.005 DBMET03517 0.214 0.008 DBMET03518 0.403 0.004 DBMET03519 0.24 0.006 DBMET03522 0.197 0.01 DBMET03520 0.184 0.011 DBMET03521 | DBMET03519 | |
| 0.314 | 0.015 | 0.392 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.315 0.015 DBMET03517 0.161 0.06 DBMET03518 0.392 0.007 DBMET03519 0.282 0.022 DBMET03522 0.282 0.023 DBMET03520 0.36 0.009 DBMET03521 | DBMET03519 | |
| 0.293 | 0.051 | 0.358 | Interleukin agonist | 0.267 0.067 DBMET03517 0.185 0.135 DBMET03518 0.317 0.04 DBMET03519 0.332 0.035 DBMET03522 0.358 0.027 DBMET03520 0.33 0.035 DBMET03521 | DBMET03520 | |
| 0.286 | 0.053 | 0.286 | HERG channel blocker | 0.174 0.107 DBMET03517 0.201 0.09 DBMET03519 0.241 0.07 DBMET03520 0.157 0.123 DBMET03521 | ||
| 0.284 | 0.055 | 0.284 | Potassium channel (Voltage-sensitive) blocker | 0.164 0.126 DBMET03517 0.178 0.113 DBMET03519 0.224 0.08 DBMET03520 | ||
| 0.233 | 0.004 | 0.248 | 5 Hydroxytryptamine 2A agonist | 0.248 0.004 DBMET03517 0.092 0.018 DBMET03518 0.162 0.005 DBMET03519 0.081 0.027 DBMET03522 0.113 0.01 DBMET03520 0.153 0.005 DBMET03521 | DBMET03517 | |
| 0.234 | 0.008 | 0.242 | 5 Hydroxytryptamine 1F antagonist | 0.11 0.027 DBMET03517 0.062 0.057 DBMET03518 0.148 0.017 DBMET03519 0.087 0.038 DBMET03522 0.242 0.008 DBMET03520 0.13 0.02 DBMET03521 | DBMET03520 | |
| 0.226 | 0.004 | 0.226 | 5 Hydroxytryptamine 5A antagonist | 0.176 0.005 DBMET03517 0.062 0.042 DBMET03518 0.114 0.013 DBMET03519 0.202 0.005 DBMET03520 0.176 0.005 DBMET03521 | ||
| 0.279 | 0.062 | 0.331 | Tumour necrosis factor alpha release inhibitor | 0.281 0.061 DBMET03517 0.331 0.043 DBMET03518 0.316 0.048 DBMET03519 0.288 0.058 DBMET03522 0.296 0.054 DBMET03520 0.188 0.119 DBMET03521 | DBMET03518 | |
| 0.223 | 0.01 | 0.223 | 5 Hydroxytryptamine uptake inhibitor | |||
| 0.217 | 0.005 | 0.217 | 5 Hydroxytryptamine 5 antagonist | 0.16 0.007 DBMET03517 0.056 0.044 DBMET03518 0.098 0.016 DBMET03519 0.175 0.005 DBMET03520 0.155 0.007 DBMET03521 | ||
| 0.225 | 0.021 | 0.263 | Death-associated protein kinase 2 inhibitor | 0.246 0.014 DBMET03517 0.205 0.031 DBMET03518 0.263 0.011 DBMET03519 0.227 0.02 DBMET03522 0.195 0.039 DBMET03520 0.178 0.056 DBMET03521 | DBMET03519 | |
| 0.253 | 0.051 | 0.401 | Death-associated protein kinase 3 inhibitor | 0.29 0.04 DBMET03517 0.165 0.101 DBMET03518 0.401 0.017 DBMET03519 0.299 0.038 DBMET03522 0.208 0.071 DBMET03520 0.298 0.038 DBMET03521 | DBMET03519 | |
| 0.208 | 0.012 | 0.312 | Protein kinase C gamma inhibitor | 0.206 0.013 DBMET03517 0.156 0.028 DBMET03518 0.252 0.006 DBMET03519 0.263 0.005 DBMET03522 0.186 0.017 DBMET03520 0.312 0.004 DBMET03521 | DBMET03521 | |
| 0.197 | 0.004 | 0.197 | Protein kinase C eta inhibitor | 0.196 0.004 DBMET03517 0.134 0.009 DBMET03518 0.176 0.005 DBMET03519 0.196 0.004 DBMET03522 0.101 0.017 DBMET03520 0.196 0.005 DBMET03521 | ||
| 0.223 | 0.033 | 0.314 | Protein kinase (CK1) inhibitor | 0.236 0.03 DBMET03517 0.314 0.016 DBMET03519 0.15 0.067 DBMET03522 0.213 0.036 DBMET03520 0.238 0.029 DBMET03521 | DBMET03519 | |
| 0.194 | 0.007 | 0.219 | Cyclin B3 inhibitor | 0.211 0.005 DBMET03517 0.181 0.008 DBMET03518 0.219 0.005 DBMET03519 0.213 0.005 DBMET03522 0.167 0.01 DBMET03520 0.142 0.015 DBMET03521 | DBMET03519 | |
| 0.209 | 0.024 | 0.218 | GABA C receptor rho-2 antagonist | 0.172 0.049 DBMET03517 0.134 0.098 DBMET03518 0.188 0.036 DBMET03519 0.218 0.02 DBMET03522 0.134 0.099 DBMET03520 0.163 0.058 DBMET03521 | DBMET03522 | |
| 0.202 | 0.02 | 0.254 | MAP kinase 13 inhibitor | 0.226 0.014 DBMET03517 0.14 0.041 DBMET03518 0.254 0.01 DBMET03519 0.175 0.027 DBMET03522 0.176 0.027 DBMET03520 0.165 0.03 DBMET03521 | DBMET03519 | |
| 0.208 | 0.03 | 0.268 | Interleukin 1 antagonist | 0.249 0.019 DBMET03517 0.199 0.033 DBMET03518 0.257 0.017 DBMET03519 0.268 0.015 DBMET03522 0.225 0.024 DBMET03520 | DBMET03522 | |
| 0.187 | 0.016 | 0.203 | Protein kinase A inhibitor | 0.202 0.013 DBMET03517 0.111 0.038 DBMET03518 0.202 0.013 DBMET03519 0.164 0.021 DBMET03522 0.1 0.045 DBMET03520 0.203 0.013 DBMET03521 | DBMET03521 | |
| 0.195 | 0.024 | 0.233 | MAP kinase 12 inhibitor | 0.22 0.017 DBMET03517 0.142 0.047 DBMET03518 0.233 0.014 DBMET03519 0.179 0.029 DBMET03522 0.156 0.038 DBMET03520 0.15 0.042 DBMET03521 | DBMET03519 | |
| 0.306 | 0.137 | 0.306 | Analgesic | 0.244 0.188 DBMET03520 | ||
| 0.174 | 0.007 | 0.194 | Protein kinase C alpha inhibitor | 0.194 0.006 DBMET03517 0.112 0.018 DBMET03518 0.167 0.008 DBMET03519 0.16 0.009 DBMET03522 0.084 0.031 DBMET03520 0.182 0.007 DBMET03521 | DBMET03517 | |
| 0.245 | 0.08 | 0.341 | 5 Hydroxytryptamine 1E antagonist | 0.195 0.137 DBMET03517 0.272 0.052 DBMET03519 0.341 0.012 DBMET03520 0.265 0.059 DBMET03521 | DBMET03520 | |
| 0.179 | 0.016 | 0.179 | Papain-like protease (SARS coronavirus) inhibitor | 0.157 0.028 DBMET03517 | ||
| 0.194 | 0.039 | 0.222 | Cyclin-dependent kinase inhibitor | 0.195 0.039 DBMET03517 0.109 0.081 DBMET03518 0.222 0.032 DBMET03519 0.128 0.069 DBMET03522 0.108 0.083 DBMET03520 0.134 0.065 DBMET03521 | DBMET03519 | |
| 0.182 | 0.028 | 0.252 | Alpha 2b adrenoreceptor antagonist | 0.13 0.05 DBMET03517 0.174 0.03 DBMET03519 0.252 0.014 DBMET03520 0.14 0.044 DBMET03521 | DBMET03520 | |
| 0.18 | 0.028 | 0.181 | Nav1.6 sodium channel blocker | 0.181 0.028 DBMET03517 0.133 0.077 DBMET03519 0.132 0.078 DBMET03522 0.121 0.095 DBMET03520 | DBMET03517 | |
| 0.181 | 0.03 | 0.338 | Alpha adrenoreceptor antagonist | 0.153 0.037 DBMET03517 0.158 0.036 DBMET03519 0.338 0.013 DBMET03520 0.1 0.057 DBMET03521 | DBMET03520 | |
| 0.153 | 0.005 | 0.166 | Protein kinase C epsilon inhibitor | 0.16 0.005 DBMET03517 0.087 0.016 DBMET03518 0.161 0.005 DBMET03519 0.134 0.008 DBMET03522 0.097 0.013 DBMET03520 0.166 0.005 DBMET03521 | DBMET03521 | |
| 0.192 | 0.045 | 0.242 | Interleukin 6 antagonist | 0.187 0.049 DBMET03517 0.189 0.047 DBMET03518 0.237 0.026 DBMET03519 0.189 0.048 DBMET03522 0.242 0.025 DBMET03520 | DBMET03520 | |
| 0.189 | 0.045 | 0.298 | Glycogen synthase kinase-3 alpha inhibitor | 0.275 0.021 DBMET03517 0.298 0.017 DBMET03519 0.265 0.023 DBMET03522 0.193 0.043 DBMET03520 0.234 0.031 DBMET03521 | DBMET03519 | |
| 0.166 | 0.022 | 0.305 | GABA C receptor antagonist | 0.305 0.004 DBMET03517 0.102 0.075 DBMET03518 0.26 0.005 DBMET03519 0.235 0.008 DBMET03522 0.14 0.036 DBMET03520 0.18 0.018 DBMET03521 | DBMET03517 | |
| 0.176 | 0.033 | 0.291 | Topoisomerase I inhibitor | 0.214 0.023 DBMET03517 0.291 0.012 DBMET03518 0.165 0.036 DBMET03519 0.203 0.026 DBMET03522 0.154 0.04 DBMET03520 0.224 0.021 DBMET03521 | DBMET03518 | |
| 0.21 | 0.067 | 0.242 | Neurotrophic factor enhancer | 0.201 0.075 DBMET03517 0.156 0.129 DBMET03518 0.242 0.043 DBMET03519 0.237 0.047 DBMET03522 0.192 0.085 DBMET03520 | DBMET03519 | |
| 0.172 | 0.03 | 0.258 | Cyclin-dependent kinase 5 inhibitor | 0.235 0.017 DBMET03517 0.148 0.042 DBMET03518 0.258 0.014 DBMET03519 0.193 0.024 DBMET03522 0.136 0.048 DBMET03520 0.092 0.083 DBMET03521 | DBMET03519 | |
| 0.288 | 0.147 | 0.404 | MAP kinase kinase 6 inhibitor | 0.32 0.117 DBMET03517 0.404 0.056 DBMET03519 0.313 0.123 DBMET03522 0.306 0.13 DBMET03520 0.326 0.112 DBMET03521 | DBMET03519 | |
| 0.17 | 0.028 | 0.228 | Interleukin 1b antagonist | 0.207 0.018 DBMET03517 0.162 0.033 DBMET03518 0.224 0.015 DBMET03519 0.228 0.014 DBMET03522 0.199 0.02 DBMET03520 | DBMET03522 | |
| 0.174 | 0.035 | 0.174 | MAO A inhibitor | 0.125 0.05 DBMET03517 0.091 0.07 DBMET03521 | ||
| 0.184 | 0.045 | 0.187 | Cyclin-dependent kinase 3 inhibitor | 0.174 0.055 DBMET03517 0.187 0.042 DBMET03518 0.176 0.053 DBMET03519 0.178 0.051 DBMET03522 0.14 0.121 DBMET03520 0.153 0.09 DBMET03521 | DBMET03518 | |
| 0.155 | 0.019 | 0.183 | Protein kinase C delta inhibitor | 0.183 0.011 DBMET03517 0.083 0.072 DBMET03518 0.159 0.018 DBMET03519 0.154 0.02 DBMET03522 0.088 0.065 DBMET03520 0.145 0.023 DBMET03521 | DBMET03517 | |
| 0.169 | 0.034 | 0.403 | 5 Hydroxytryptamine 2B antagonist | 0.152 0.04 DBMET03517 0.198 0.027 DBMET03519 0.11 0.072 DBMET03522 0.403 0.008 DBMET03520 0.321 0.013 DBMET03521 | DBMET03520 | |
| 0.155 | 0.019 | 0.271 | Protein kinase C zeta inhibitor | 0.228 0.009 DBMET03517 0.249 0.007 DBMET03519 0.171 0.016 DBMET03522 0.143 0.022 DBMET03520 0.271 0.006 DBMET03521 | DBMET03521 | |
| 0.156 | 0.021 | 0.266 | Alpha 1b adrenoreceptor antagonist | 0.123 0.028 DBMET03517 0.148 0.022 DBMET03519 0.266 0.009 DBMET03520 0.086 0.042 DBMET03521 | DBMET03520 | |
| 0.14 | 0.005 | 0.175 | Protein kinase C beta inhibitor | 0.15 0.004 DBMET03517 0.101 0.013 DBMET03518 0.139 0.005 DBMET03519 0.151 0.004 DBMET03522 0.12 0.007 DBMET03520 0.175 0.004 DBMET03521 | DBMET03521 | |
| 0.157 | 0.022 | 0.275 | 5 Hydroxytryptamine 1 antagonist | 0.103 0.036 DBMET03517 0.187 0.018 DBMET03519 0.275 0.011 DBMET03520 0.181 0.019 DBMET03521 | DBMET03520 | |
| 0.144 | 0.013 | 0.297 | 5 Hydroxytryptamine 1B antagonist | 0.084 0.032 DBMET03517 0.11 0.019 DBMET03519 0.297 0.005 DBMET03520 0.109 0.02 DBMET03521 | DBMET03520 | |
| 0.152 | 0.023 | 0.238 | Alpha 1a adrenoreceptor antagonist | 0.102 0.035 DBMET03517 0.142 0.025 DBMET03519 0.238 0.013 DBMET03520 0.074 0.048 DBMET03521 | DBMET03520 | |
| 0.134 | 0.005 | 0.191 | 5 Hydroxytryptamine 2C agonist | 0.191 0.004 DBMET03517 0.077 0.012 DBMET03518 0.11 0.007 DBMET03519 0.071 0.014 DBMET03522 0.069 0.015 DBMET03520 0.124 0.005 DBMET03521 | DBMET03517 | |
| 0.163 | 0.036 | 0.164 | Cyclin-dependent kinase 1 inhibitor | 0.145 0.043 DBMET03517 0.094 0.07 DBMET03518 0.164 0.035 DBMET03519 0.105 0.063 DBMET03522 0.086 0.077 DBMET03520 | DBMET03519 | |
| 0.137 | 0.011 | 0.137 | Adrenaline uptake inhibitor | |||
| 0.155 | 0.028 | 0.327 | Alpha 1 adrenoreceptor antagonist | 0.098 0.044 DBMET03517 0.153 0.029 DBMET03519 0.327 0.009 DBMET03520 0.077 0.055 DBMET03521 | DBMET03520 | |
| 0.157 | 0.032 | 0.171 | GABA receptor agonist | 0.171 0.026 DBMET03517 0.163 0.03 DBMET03518 0.138 0.043 DBMET03520 0.091 0.088 DBMET03521 | DBMET03517 | |
| 0.165 | 0.042 | 0.313 | TRKA antagonist | 0.198 0.031 DBMET03517 0.104 0.084 DBMET03518 0.313 0.011 DBMET03519 0.131 0.06 DBMET03522 0.22 0.025 DBMET03520 0.277 0.015 DBMET03521 | DBMET03519 | |
| 0.14 | 0.02 | 0.142 | MAP kinase 11 inhibitor | 0.1 0.035 DBMET03517 0.078 0.049 DBMET03518 0.142 0.019 DBMET03519 0.068 0.057 DBMET03522 0.099 0.036 DBMET03520 0.078 0.05 DBMET03521 | DBMET03519 | |
| 0.153 | 0.034 | 0.208 | Polo-like kinase-4 inhibitor | 0.153 0.034 DBMET03517 0.1 0.077 DBMET03518 0.185 0.019 DBMET03519 0.143 0.04 DBMET03522 0.208 0.014 DBMET03520 0.188 0.019 DBMET03521 | DBMET03520 | |
| 0.181 | 0.062 | 0.212 | MAP kinase kinase 5 inhibitor | 0.188 0.048 DBMET03517 0.16 0.114 DBMET03518 0.212 0.022 DBMET03519 0.181 0.061 DBMET03520 0.195 0.038 DBMET03521 | DBMET03519 | |
| 0.164 | 0.045 | 0.227 | Protein kinase (CK1) delta inhibitor | 0.184 0.035 DBMET03517 0.227 0.021 DBMET03519 0.129 0.067 DBMET03522 0.167 0.043 DBMET03520 0.166 0.044 DBMET03521 | DBMET03519 | |
| 0.162 | 0.043 | 0.222 | MAP kinase kinase 4 inhibitor | 0.175 0.028 DBMET03517 0.148 0.066 DBMET03518 0.222 0.008 DBMET03519 0.197 0.015 DBMET03522 0.169 0.033 DBMET03520 0.213 0.01 DBMET03521 | DBMET03519 | |
| 0.122 | 0.004 | 0.163 | 5 Hydroxytryptamine 2B agonist | 0.163 0.003 DBMET03517 0.051 0.013 DBMET03518 0.099 0.004 DBMET03519 0.044 0.019 DBMET03522 0.048 0.014 DBMET03520 0.066 0.007 DBMET03521 | DBMET03517 | |
| 0.132 | 0.015 | 0.132 | Cyclin-dependent kinase 4 inhibitor | 0.123 0.017 DBMET03517 0.087 0.031 DBMET03518 0.116 0.02 DBMET03519 0.092 0.029 DBMET03522 0.061 0.05 DBMET03520 0.103 0.025 DBMET03521 | ||
| 0.141 | 0.027 | 0.264 | NMDA receptor antagonist | 0.23 0.011 DBMET03517 0.086 0.058 DBMET03519 0.264 0.008 DBMET03522 | DBMET03522 | |
| 0.146 | 0.033 | 0.387 | Check point kinase 2 inhibitor | 0.216 0.014 DBMET03517 0.104 0.061 DBMET03518 0.387 0.004 DBMET03519 0.162 0.028 DBMET03522 0.235 0.011 DBMET03520 0.312 0.005 DBMET03521 | DBMET03519 | |
| 0.146 | 0.034 | 0.169 | Alpha 2c adrenoreceptor antagonist | 0.097 0.069 DBMET03517 0.109 0.058 DBMET03519 0.169 0.025 DBMET03520 0.086 0.08 DBMET03521 | DBMET03520 | |
| 0.154 | 0.044 | 0.174 | Glycogen synthase kinase-3 inhibitor | 0.174 0.038 DBMET03517 0.112 0.068 DBMET03518 0.169 0.039 DBMET03519 0.121 0.061 DBMET03522 0.093 0.086 DBMET03520 0.102 0.078 DBMET03521 | DBMET03517 | |
| 0.15 | 0.044 | 0.157 | Glycogen synthase kinase-3 beta inhibitor | 0.157 0.04 DBMET03517 0.113 0.066 DBMET03518 0.157 0.04 DBMET03519 0.118 0.063 DBMET03522 0.104 0.073 DBMET03521 | DBMET03519 | |
| 0.162 | 0.061 | 0.284 | Protein kinase (CK1) gamma inhibitor | 0.219 0.038 DBMET03517 0.284 0.021 DBMET03519 0.159 0.062 DBMET03522 0.108 0.105 DBMET03520 0.138 0.075 DBMET03521 | DBMET03519 | |
| 0.159 | 0.059 | 0.25 | Ribosomal protein S6 kinase inhibitor | 0.223 0.029 DBMET03517 0.11 0.103 DBMET03518 0.25 0.02 DBMET03519 0.141 0.072 DBMET03522 0.113 0.099 DBMET03520 0.223 0.029 DBMET03521 | DBMET03519 | |
| 0.131 | 0.032 | 0.224 | GABA C receptor rho-1 antagonist | 0.141 0.026 DBMET03517 0.224 0.005 DBMET03519 0.214 0.006 DBMET03522 0.133 0.03 DBMET03520 0.175 0.013 DBMET03521 | DBMET03519 | |
| 0.106 | 0.007 | 0.128 | Kinesin-like protein 1 inhibitor | 0.122 0.005 DBMET03517 0.048 0.017 DBMET03518 0.128 0.005 DBMET03519 0.071 0.012 DBMET03522 0.125 0.005 DBMET03520 0.061 0.014 DBMET03521 | DBMET03519 | |
| 0.106 | 0.007 | 0.128 | Kinesin antagonist | 0.122 0.005 DBMET03517 0.048 0.017 DBMET03518 0.128 0.005 DBMET03519 0.071 0.012 DBMET03522 0.125 0.005 DBMET03520 0.061 0.014 DBMET03521 | DBMET03519 | |
| 0.14 | 0.042 | 0.152 | DNA repair enzyme inhibitor | 0.152 0.03 DBMET03517 0.138 0.044 DBMET03519 0.121 0.07 DBMET03522 0.133 0.051 DBMET03520 0.134 0.049 DBMET03521 | DBMET03517 | |
| 0.157 | 0.061 | 0.299 | Tyrosine-protein kinase receptor antagonist | 0.18 0.049 DBMET03517 0.299 0.017 DBMET03519 0.123 0.084 DBMET03522 0.252 0.026 DBMET03520 0.258 0.025 DBMET03521 | DBMET03519 | |
| 0.137 | 0.041 | 0.197 | MAP kinase kinase kinase inhibitor | 0.151 0.035 DBMET03517 0.108 0.059 DBMET03518 0.197 0.019 DBMET03519 0.092 0.074 DBMET03522 0.11 0.057 DBMET03520 0.155 0.033 DBMET03521 | DBMET03519 | |
| 0.186 | 0.091 | 0.421 | MAP kinase kinase 2 inhibitor | 0.24 0.058 DBMET03517 0.189 0.089 DBMET03518 0.38 0.015 DBMET03519 0.195 0.085 DBMET03522 0.31 0.032 DBMET03520 0.421 0.009 DBMET03521 | DBMET03521 | |
| 0.141 | 0.047 | 0.273 | DNA intercalator | 0.146 0.044 DBMET03517 0.273 0.014 DBMET03518 0.089 0.087 DBMET03519 0.102 0.072 DBMET03522 0.115 0.061 DBMET03520 0.145 0.045 DBMET03521 | DBMET03518 | |
| 0.165 | 0.074 | 0.197 | Catenin beta inhibitor | 0.152 0.102 DBMET03517 0.148 0.11 DBMET03519 0.197 0.034 DBMET03522 0.14 0.132 DBMET03520 | DBMET03522 | |
| 0.158 | 0.067 | 0.16 | Acetylcholine M1 receptor antagonist | 0.147 0.077 DBMET03517 0.16 0.065 DBMET03518 0.12 0.108 DBMET03520 0.128 0.098 DBMET03521 | DBMET03518 | |
| 0.111 | 0.02 | 0.123 | Benzodiazepine agonist | 0.081 0.039 DBMET03517 0.081 0.038 DBMET03519 0.066 0.057 DBMET03522 0.118 0.017 DBMET03520 0.123 0.015 DBMET03521 | DBMET03521 | |
| 0.228 | 0.137 | 0.228 | Ca(v)3.3 blocker | |||
| 0.126 | 0.035 | 0.198 | Antineoplastic alkaloid | 0.198 0.014 DBMET03517 0.113 0.041 DBMET03518 0.114 0.04 DBMET03519 0.162 0.024 DBMET03522 0.127 0.035 DBMET03520 0.14 0.03 DBMET03521 | DBMET03517 | |
| 0.11 | 0.021 | 0.119 | Cyclin E inhibitor | 0.119 0.018 DBMET03517 0.083 0.031 DBMET03518 0.117 0.018 DBMET03519 0.064 0.039 DBMET03522 0.057 0.043 DBMET03520 0.098 0.025 DBMET03521 | DBMET03517 | |
| 0.106 | 0.018 | 0.113 | Cyclin E1 inhibitor | 0.113 0.016 DBMET03517 0.078 0.025 DBMET03518 0.111 0.016 DBMET03519 0.061 0.032 DBMET03522 0.048 0.038 DBMET03520 0.089 0.022 DBMET03521 | DBMET03517 | |
| 0.111 | 0.024 | 0.161 | Phosphodiesterase 11A inhibitor | 0.158 0.009 DBMET03517 0.1 0.032 DBMET03518 0.119 0.021 DBMET03519 0.161 0.008 DBMET03520 | DBMET03520 | |
| 0.111 | 0.024 | 0.161 | Phosphodiesterase XI inhibitor | 0.158 0.009 DBMET03517 0.1 0.032 DBMET03518 0.119 0.021 DBMET03519 0.161 0.008 DBMET03520 | DBMET03520 | |
| 0.204 | 0.117 | 0.303 | DNA synthesis inhibitor | 0.211 0.107 DBMET03517 0.186 0.145 DBMET03519 0.303 0.043 DBMET03522 0.173 0.164 DBMET03520 0.229 0.084 DBMET03521 | DBMET03522 | |
| 0.101 | 0.014 | 0.101 | CDK4/cyclin D1 inhibitor | 0.1 0.014 DBMET03517 0.08 0.024 DBMET03518 0.084 0.022 DBMET03519 0.074 0.028 DBMET03522 0.077 0.026 DBMET03521 | ||
| 0.138 | 0.054 | 0.25 | Protein kinase (CK1) gamma 2 inhibitor | 0.184 0.037 DBMET03517 0.25 0.02 DBMET03519 0.132 0.057 DBMET03522 0.108 0.075 DBMET03521 | DBMET03519 | |
| 0.09 | 0.009 | 0.09 | 5 Hydroxytryptamine 7 agonist | 0.055 0.041 DBMET03517 0.068 0.021 DBMET03519 0.069 0.02 DBMET03520 0.071 0.018 DBMET03521 | ||
| 0.091 | 0.011 | 0.099 | Cyclin B2 inhibitor | 0.098 0.009 DBMET03517 0.078 0.016 DBMET03518 0.099 0.009 DBMET03519 0.095 0.01 DBMET03522 0.069 0.022 DBMET03520 0.05 0.047 DBMET03521 | DBMET03519 | |
| 0.116 | 0.043 | 0.116 | CDK/cyclin complex inhibitor | 0.115 0.044 DBMET03517 0.102 0.05 DBMET03518 0.116 0.043 DBMET03519 0.076 0.073 DBMET03521 | ||
| 0.105 | 0.033 | 0.115 | GABA A receptor agonist | 0.107 0.032 DBMET03517 0.115 0.027 DBMET03518 0.089 0.05 DBMET03520 | DBMET03518 | |
| 0.085 | 0.013 | 0.094 | Cyclin B inhibitor | 0.093 0.011 DBMET03517 0.072 0.02 DBMET03518 0.094 0.011 DBMET03519 0.088 0.013 DBMET03522 0.064 0.027 DBMET03520 | DBMET03519 | |
| 0.088 | 0.016 | 0.095 | Cyclin B1 inhibitor | 0.093 0.014 DBMET03517 0.077 0.025 DBMET03518 0.095 0.013 DBMET03519 0.09 0.015 DBMET03522 0.069 0.033 DBMET03520 | DBMET03519 | |
| 0.102 | 0.03 | 0.142 | Glycine receptor antagonist | 0.096 0.036 DBMET03517 0.09 0.043 DBMET03519 0.142 0.009 DBMET03522 0.078 0.061 DBMET03520 | DBMET03522 | |
| 0.178 | 0.108 | 0.178 | Potassium channel blocker | |||
| 0.079 | 0.009 | 0.117 | Glutamate (mGluR1a) antagonist | 0.066 0.012 DBMET03517 0.074 0.01 DBMET03518 0.108 0.005 DBMET03519 0.117 0.004 DBMET03522 0.07 0.011 DBMET03520 0.038 0.033 DBMET03521 | DBMET03522 | |
| 0.142 | 0.073 | 0.157 | Vascular endothelial growth factor 3 antagonist | 0.125 0.089 DBMET03517 0.157 0.062 DBMET03519 0.146 0.069 DBMET03521 | DBMET03519 | |
| 0.125 | 0.056 | 0.168 | Interleukin 8 antagonist | 0.117 0.065 DBMET03517 0.117 0.066 DBMET03518 0.122 0.058 DBMET03519 0.168 0.024 DBMET03522 0.116 0.067 DBMET03520 | DBMET03522 | |
| 0.09 | 0.022 | 0.11 | Phospholipase D inhibitor | 0.08 0.035 DBMET03517 0.065 0.064 DBMET03518 0.109 0.01 DBMET03519 0.11 0.01 DBMET03522 0.088 0.024 DBMET03520 0.08 0.034 DBMET03521 | DBMET03522 | |
| 0.12 | 0.052 | 0.184 | Cyclin-dependent kinase 2 inhibitor | 0.153 0.036 DBMET03517 0.099 0.071 DBMET03518 0.184 0.028 DBMET03519 0.1 0.07 DBMET03522 0.142 0.041 DBMET03521 | DBMET03519 | |
| 0.169 | 0.101 | 0.216 | Focal adhesion kinase 2 inhibitor | 0.216 0.057 DBMET03519 0.161 0.113 DBMET03522 0.161 0.113 DBMET03520 0.196 0.073 DBMET03521 | DBMET03519 | |
| 0.101 | 0.034 | 0.123 | Myeloperoxidase inhibitor | 0.123 0.018 DBMET03517 | DBMET03517 | |
| 0.076 | 0.01 | 0.076 | Antiviral (Hepatitis D) | 0.065 0.018 DBMET03517 0.06 0.022 DBMET03518 0.066 0.016 DBMET03519 0.074 0.011 DBMET03522 0.07 0.013 DBMET03520 0.058 0.024 DBMET03521 | ||
| 0.07 | 0.006 | 0.086 | Acid-sensing ion channel blocker | 0.081 0.005 DBMET03517 0.063 0.008 DBMET03518 0.08 0.005 DBMET03519 0.084 0.004 DBMET03522 0.086 0.004 DBMET03520 0.051 0.015 DBMET03521 | DBMET03520 | |
| 0.097 | 0.033 | 0.16 | Dopamine D2 antagonist | 0.065 0.047 DBMET03517 0.094 0.034 DBMET03518 0.075 0.042 DBMET03519 0.16 0.021 DBMET03520 | DBMET03520 | |
| 0.099 | 0.039 | 0.163 | Dopamine antagonist | 0.068 0.055 DBMET03517 0.087 0.044 DBMET03518 0.08 0.048 DBMET03519 0.163 0.023 DBMET03520 0.063 0.06 DBMET03521 | DBMET03520 | |
| 0.097 | 0.038 | 0.109 | Alpha 2a adrenoreceptor antagonist | 0.109 0.032 DBMET03517 0.078 0.05 DBMET03519 0.108 0.033 DBMET03520 0.072 0.056 DBMET03521 | DBMET03517 | |
| 0.109 | 0.05 | 0.156 | Pim-1 kinase inhibitor | 0.143 0.03 DBMET03517 0.156 0.025 DBMET03519 0.127 0.038 DBMET03522 0.117 0.044 DBMET03521 | DBMET03519 | |
| 0.141 | 0.082 | 0.169 | MAP kinase 3 inhibitor | 0.126 0.119 DBMET03517 0.169 0.044 DBMET03519 0.141 0.083 DBMET03522 0.148 0.071 DBMET03520 0.149 0.069 DBMET03521 | DBMET03519 | |
| 0.092 | 0.035 | 0.153 | 5 Hydroxytryptamine 1A antagonist | 0.088 0.037 DBMET03517 0.129 0.024 DBMET03519 0.153 0.02 DBMET03520 0.106 0.03 DBMET03521 | DBMET03520 | |
| 0.153 | 0.098 | 0.27 | TRKC antagonist | 0.157 0.096 DBMET03517 0.133 0.117 DBMET03518 0.27 0.04 DBMET03519 0.128 0.123 DBMET03522 0.233 0.054 DBMET03520 0.27 0.04 DBMET03521 | DBMET03521 | |
| 0.125 | 0.071 | 0.125 | MAO inhibitor | 0.119 0.075 DBMET03517 | ||
| 0.08 | 0.026 | 0.136 | Protein kinase C iota inhibitor | 0.136 0.011 DBMET03517 0.055 0.045 DBMET03518 0.12 0.014 DBMET03519 0.075 0.029 DBMET03522 0.091 0.021 DBMET03521 | DBMET03517 | |
| 0.079 | 0.026 | 0.135 | TRPA1 antagonist | 0.135 0.012 DBMET03520 | DBMET03520 | |
| 0.102 | 0.049 | 0.133 | Phosphodiesterase 6D inhibitor | 0.1 0.053 DBMET03517 0.102 0.047 DBMET03519 0.133 0.016 DBMET03522 0.13 0.017 DBMET03520 0.091 0.072 DBMET03521 | DBMET03522 | |
| 0.082 | 0.03 | 0.24 | 5 Hydroxytryptamine 1D antagonist | 0.065 0.043 DBMET03517 0.12 0.017 DBMET03519 0.24 0.005 DBMET03520 0.123 0.016 DBMET03521 | DBMET03520 | |
| 0.104 | 0.053 | 0.115 | Nitric-oxide synthase inhibitor | 0.115 0.041 DBMET03517 | DBMET03517 | |
| 0.133 | 0.083 | 0.18 | CDC-like kinase 1 inhibitor | 0.176 0.051 DBMET03517 0.18 0.048 DBMET03519 0.139 0.078 DBMET03522 0.16 0.063 DBMET03520 | DBMET03519 | |
| 0.074 | 0.025 | 0.074 | CDK4/cyclin D inhibitor | 0.073 0.025 DBMET03517 0.057 0.043 DBMET03518 0.065 0.032 DBMET03519 0.056 0.045 DBMET03522 0.062 0.036 DBMET03521 | ||
| 0.075 | 0.027 | 0.08 | Acetylcholine M5 receptor antagonist | 0.08 0.024 DBMET03518 | DBMET03518 | |
| 0.144 | 0.097 | 0.26 | CDC-like kinase 2 inhibitor | 0.215 0.059 DBMET03517 0.26 0.042 DBMET03519 0.147 0.095 DBMET03522 0.131 0.108 DBMET03520 | DBMET03519 | |
| 0.054 | 0.007 | 0.082 | AMPA 3 receptor antagonist | 0.052 0.008 DBMET03517 0.033 0.018 DBMET03518 0.032 0.019 DBMET03519 0.082 0.004 DBMET03522 | DBMET03522 | |
| 0.096 | 0.051 | 0.096 | Alpha 2 adrenoreceptor antagonist | 0.095 0.052 DBMET03517 0.092 0.054 DBMET03520 | ||
| 0.077 | 0.033 | 0.1 | 5 Hydroxytryptamine 7 antagonist | 0.059 0.046 DBMET03517 0.062 0.044 DBMET03519 0.1 0.025 DBMET03520 0.068 0.038 DBMET03521 | DBMET03520 | |
| 0.193 | 0.149 | 0.254 | Tyrosine 3 hydroxylase inhibitor | 0.243 0.076 DBMET03517 0.254 0.065 DBMET03519 0.251 0.067 DBMET03522 0.247 0.071 DBMET03520 0.197 0.141 DBMET03521 | DBMET03519 | |
| 0.091 | 0.046 | 0.103 | Inducible nitric-oxide synthase inhibitor | 0.103 0.035 DBMET03517 | DBMET03517 | |
| 0.076 | 0.032 | 0.22 | Alpha 1d adrenoreceptor antagonist | 0.06 0.041 DBMET03517 0.105 0.022 DBMET03519 0.22 0.008 DBMET03520 0.055 0.045 DBMET03521 | DBMET03520 | |
| 0.085 | 0.042 | 0.085 | Acetylcholine M4 receptor antagonist | 0.08 0.047 DBMET03521 | ||
| 0.165 | 0.122 | 0.269 | Dyrk kinase inhibitor | 0.203 0.097 DBMET03517 0.269 0.063 DBMET03519 0.224 0.085 DBMET03522 0.184 0.108 DBMET03520 | DBMET03519 | |
| 0.07 | 0.028 | 0.139 | Cyclin D1 inhibitor | 0.088 0.012 DBMET03517 0.083 0.016 DBMET03518 0.115 0.005 DBMET03519 0.076 0.022 DBMET03522 0.102 0.007 DBMET03520 0.139 0.004 DBMET03521 | DBMET03521 | |
| 0.09 | 0.049 | 0.121 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.08 0.063 DBMET03517 0.085 0.055 DBMET03519 0.121 0.024 DBMET03522 0.077 0.068 DBMET03520 | DBMET03522 | |
| 0.106 | 0.066 | 0.124 | CDC-like kinase 3 inhibitor | 0.124 0.038 DBMET03517 0.096 0.089 DBMET03518 0.108 0.062 DBMET03519 0.103 0.072 DBMET03522 0.111 0.057 DBMET03520 | DBMET03517 | |
| 0.047 | 0.007 | 0.051 | Protein kinase C beta II inhibitor | 0.044 0.009 DBMET03517 0.042 0.009 DBMET03518 0.045 0.008 DBMET03519 0.051 0.005 DBMET03522 0.036 0.016 DBMET03520 0.044 0.008 DBMET03521 | DBMET03522 | |
| 0.141 | 0.102 | 0.289 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | 0.188 0.071 DBMET03517 0.289 0.035 DBMET03519 0.147 0.098 DBMET03522 0.188 0.071 DBMET03520 0.166 0.083 DBMET03521 | DBMET03519 | |
| 0.062 | 0.024 | 0.143 | AMPA receptor antagonist | 0.075 0.019 DBMET03517 0.046 0.035 DBMET03519 0.143 0.006 DBMET03522 0.056 0.027 DBMET03520 | DBMET03522 | |
| 0.075 | 0.039 | 0.169 | CDC7 inhibitor | 0.114 0.018 DBMET03517 0.169 0.008 DBMET03519 0.075 0.039 DBMET03522 0.068 0.046 DBMET03520 0.115 0.017 DBMET03521 | DBMET03519 | |
| 0.043 | 0.006 | 0.043 | Protein kinase C beta I inhibitor | 0.041 0.008 DBMET03517 0.032 0.027 DBMET03518 0.035 0.017 DBMET03519 0.042 0.007 DBMET03522 0.039 0.01 DBMET03521 | ||
| 0.067 | 0.033 | 0.081 | Glutamate (mGluR1) antagonist | 0.081 0.023 DBMET03522 | DBMET03522 | |
| 0.059 | 0.025 | 0.059 | Dopamine transporter inhibitor | |||
| 0.126 | 0.093 | 0.155 | Death-associated protein kinase 1 inhibitor | 0.136 0.065 DBMET03517 0.155 0.032 DBMET03519 0.132 0.075 DBMET03522 | DBMET03519 | |
| 0.098 | 0.064 | 0.098 | Glutamate (mGluR7) agonist | |||
| 0.157 | 0.124 | 0.258 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.19 0.099 DBMET03517 0.258 0.064 DBMET03519 0.225 0.079 DBMET03522 0.182 0.104 DBMET03520 | DBMET03519 | |
| 0.148 | 0.116 | 0.231 | Clk dual-specificity kinase inhibitor | 0.192 0.084 DBMET03517 0.231 0.063 DBMET03519 0.148 0.115 DBMET03520 | DBMET03519 | |
| 0.076 | 0.045 | 0.102 | Phosphodiesterase V inhibitor | 0.068 0.054 DBMET03517 0.062 0.061 DBMET03519 0.066 0.056 DBMET03522 0.102 0.027 DBMET03520 | DBMET03520 | |
| 0.069 | 0.041 | 0.105 | Dopamine D1 antagonist | 0.062 0.048 DBMET03517 0.105 0.024 DBMET03520 | DBMET03520 | |
| 0.101 | 0.075 | 0.176 | 5 Hydroxytryptamine 3A agonist | 0.155 0.032 DBMET03517 0.168 0.027 DBMET03519 0.176 0.023 DBMET03520 0.154 0.033 DBMET03521 | DBMET03520 | |
| 0.076 | 0.05 | 0.099 | MAP kinase 14 inhibitor | 0.069 0.056 DBMET03517 0.099 0.035 DBMET03519 0.078 0.048 DBMET03520 | DBMET03519 | |
| 0.095 | 0.069 | 0.174 | Insulin receptor antagonist | 0.089 0.08 DBMET03517 0.138 0.032 DBMET03519 0.129 0.037 DBMET03520 0.174 0.02 DBMET03521 | DBMET03521 | |
| 0.066 | 0.041 | 0.066 | CDK1/cyclin B inhibitor | 0.062 0.045 DBMET03517 0.056 0.05 DBMET03519 | ||
| 0.188 | 0.163 | 0.269 | MAP kinase kinase 3 inhibitor | 0.215 0.085 DBMET03517 0.269 0.018 DBMET03519 0.23 0.057 DBMET03520 0.257 0.025 DBMET03521 | DBMET03519 | |
| 0.072 | 0.048 | 0.1 | Phosphodiesterase 5A inhibitor | 0.064 0.056 DBMET03517 0.063 0.059 DBMET03522 0.1 0.027 DBMET03520 | DBMET03520 | |
| 0.057 | 0.034 | 0.088 | 5 Hydroxytryptamine 1 agonist | 0.075 0.027 DBMET03519 0.088 0.023 DBMET03520 0.051 0.037 DBMET03521 | DBMET03520 | |
| 0.106 | 0.083 | 0.106 | Acetylcholine muscarinic antagonist | 0.098 0.094 DBMET03518 | ||
| 0.135 | 0.113 | 0.191 | CDC-like kinase 4 inhibitor | 0.171 0.085 DBMET03517 0.191 0.072 DBMET03519 | DBMET03519 | |
| 0.042 | 0.021 | 0.069 | Protein kinase (CK1) epsilon inhibitor | 0.044 0.019 DBMET03517 0.05 0.013 DBMET03519 0.069 0.006 DBMET03520 0.043 0.02 DBMET03521 | DBMET03520 | |
| 0.083 | 0.062 | 0.099 | 3C-Like protease (SARS coronavirus) inhibitor | 0.081 0.067 DBMET03517 0.081 0.064 DBMET03518 0.097 0.036 DBMET03519 0.099 0.034 DBMET03522 0.093 0.042 DBMET03521 | DBMET03522 | |
| 0.108 | 0.087 | 0.175 | Glutamate receptor antagonist | 0.152 0.05 DBMET03517 0.137 0.06 DBMET03519 0.175 0.036 DBMET03522 0.127 0.068 DBMET03520 | DBMET03522 | |
| 0.086 | 0.065 | 0.151 | Pim-3 kinase inhibitor | 0.131 0.025 DBMET03517 0.151 0.018 DBMET03519 0.093 0.053 DBMET03520 0.111 0.036 DBMET03521 | DBMET03519 | |
| 0.056 | 0.036 | 0.103 | Pim-2 kinase inhibitor | 0.093 0.017 DBMET03517 0.103 0.014 DBMET03519 0.052 0.042 DBMET03520 0.064 0.027 DBMET03521 | DBMET03519 | |
| 0.086 | 0.067 | 0.122 | Potassium channel activator | 0.122 0.031 DBMET03518 | DBMET03518 | |
| 0.142 | 0.123 | 0.238 | Psychostimulant | 0.155 0.112 DBMET03519 0.238 0.063 DBMET03520 0.15 0.116 DBMET03521 | DBMET03520 | |
| 0.102 | 0.084 | 0.207 | Topoisomerase II inhibitor | 0.114 0.072 DBMET03517 0.207 0.032 DBMET03518 0.153 0.048 DBMET03522 0.111 0.075 DBMET03521 | DBMET03518 | |
| 0.057 | 0.039 | 0.057 | 5 Hydroxytryptamine 6 antagonist | 0.055 0.041 DBMET03517 0.05 0.049 DBMET03521 | ||
| 0.194 | 0.176 | 0.22 | Angiogenesis inhibitor | 0.22 0.148 DBMET03519 0.193 0.178 DBMET03521 | DBMET03519 | |
| 0.136 | 0.119 | 0.245 | Tumour necrosis factor antagonist | 0.144 0.108 DBMET03517 0.24 0.034 DBMET03519 0.162 0.086 DBMET03522 0.245 0.032 DBMET03520 | DBMET03520 | |
| 0.038 | 0.023 | 0.14 | Kainate receptor 2 antagonist | 0.083 0.006 DBMET03517 0.042 0.02 DBMET03518 0.064 0.01 DBMET03519 0.14 0.004 DBMET03522 0.05 0.016 DBMET03520 | DBMET03522 | |
| 0.032 | 0.019 | 0.101 | AMPA 1 receptor antagonist | 0.032 0.019 DBMET03517 0.101 0.005 DBMET03522 | DBMET03522 | |
| 0.076 | 0.062 | 0.1 | Histamine H1 receptor antagonist | 0.081 0.057 DBMET03522 0.1 0.041 DBMET03520 0.08 0.058 DBMET03521 | DBMET03520 | |
| 0.14 | 0.126 | 0.246 | Interleukin antagonist | 0.199 0.085 DBMET03517 0.239 0.066 DBMET03519 0.246 0.063 DBMET03522 0.21 0.079 DBMET03520 | DBMET03522 | |
| 0.028 | 0.015 | 0.053 | Kainate receptor 4 antagonist | 0.032 0.013 DBMET03517 0.033 0.012 DBMET03518 0.036 0.011 DBMET03519 0.053 0.006 DBMET03522 0.034 0.012 DBMET03520 | DBMET03522 | |
| 0.031 | 0.019 | 0.046 | AMPA 2 receptor antagonist | 0.031 0.019 DBMET03517 0.046 0.012 DBMET03522 | DBMET03522 | |
| 0.05 | 0.038 | 0.05 | H+/K+-transporting ATPase inhibitor | |||
| 0.084 | 0.072 | 0.084 | Antihistaminic | |||
| 0.129 | 0.118 | 0.215 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.136 0.102 DBMET03517 0.215 0.012 DBMET03519 0.185 0.028 DBMET03522 0.192 0.023 DBMET03520 0.185 0.028 DBMET03521 | DBMET03519 | |
| 0.035 | 0.024 | 0.069 | Somatostatin 5 agonist | 0.069 0.008 DBMET03517 0.033 0.027 DBMET03518 0.04 0.019 DBMET03519 | DBMET03517 | |
| 0.029 | 0.02 | 0.043 | 5 Hydroxytryptamine 1D agonist | 0.043 0.013 DBMET03520 | DBMET03520 | |
| 0.029 | 0.023 | 0.042 | Dipeptidyl peptidase I inhibitor | 0.034 0.017 DBMET03517 0.032 0.019 DBMET03518 0.042 0.011 DBMET03519 0.039 0.013 DBMET03520 0.04 0.012 DBMET03521 | DBMET03519 | |
| 0.113 | 0.106 | 0.214 | Protein kinase (CK1) gamma 1 inhibitor | 0.156 0.064 DBMET03517 0.214 0.038 DBMET03519 0.112 0.108 DBMET03520 | DBMET03519 | |
| 0.078 | 0.073 | 0.095 | Antiadrenergic | 0.095 0.059 DBMET03520 | DBMET03520 | |
| 0.053 | 0.048 | 0.066 | Protein kinase C theta inhibitor | 0.066 0.028 DBMET03517 | DBMET03517 | |
| 0.05 | 0.046 | 0.07 | Myc inhibitor | 0.058 0.033 DBMET03519 0.07 0.019 DBMET03522 0.062 0.027 DBMET03521 | DBMET03522 | |
| 0.062 | 0.059 | 0.062 | CDK2/cyclin E2 inhibitor | 0.062 0.06 DBMET03519 | ||
| 0.075 | 0.072 | 0.111 | Androgen antagonist | 0.079 0.067 DBMET03518 0.089 0.055 DBMET03519 0.111 0.039 DBMET03522 0.084 0.06 DBMET03520 0.102 0.045 DBMET03521 | DBMET03522 | |
| 0.066 | 0.062 | 0.072 | Rho-associated kinase I inhibitor | 0.072 0.054 DBMET03517 0.065 0.064 DBMET03519 | DBMET03517 | |
| 0.039 | 0.036 | 0.089 | NMDA receptor subunit 3B antagonist | 0.049 0.026 DBMET03517 0.089 0.012 DBMET03522 | DBMET03522 | |
| 0.026 | 0.023 | 0.049 | Cyclin E2 inhibitor | 0.049 0.009 DBMET03517 0.026 0.022 DBMET03518 0.043 0.011 DBMET03519 0.025 0.024 DBMET03520 0.045 0.01 DBMET03521 | DBMET03517 | |
| 0.071 | 0.069 | 0.13 | TIE antagonist | 0.102 0.04 DBMET03519 0.13 0.028 DBMET03521 | DBMET03521 | |
| 0.063 | 0.062 | 0.109 | MDM2 inhibitor | 0.067 0.049 DBMET03517 0.066 0.052 DBMET03518 0.082 0.018 DBMET03519 0.109 0.005 DBMET03522 0.077 0.023 DBMET03520 0.076 0.026 DBMET03521 | DBMET03522 | |
| 0.074 | 0.074 | 0.092 | Adrenaline antagonist | 0.092 0.059 DBMET03520 | DBMET03520 | |
| 0.069 | 0.07 | 0.129 | TIE-2 antagonist | 0.1 0.039 DBMET03519 0.129 0.027 DBMET03521 | DBMET03521 | |
| 0.041 | 0.042 | 0.082 | Glutamate (mGluR group I) agonist | 0.046 0.035 DBMET03517 0.072 0.015 DBMET03519 0.042 0.04 DBMET03522 0.076 0.014 DBMET03520 0.082 0.012 DBMET03521 | DBMET03521 | |
| 0.035 | 0.037 | 0.085 | CDK5/p25 inhibitor | 0.067 0.012 DBMET03517 0.085 0.008 DBMET03519 0.063 0.014 DBMET03522 | DBMET03519 | |
| 0.064 | 0.066 | 0.113 | Rho-associated kinase II inhibitor | 0.113 0.027 DBMET03517 0.084 0.042 DBMET03519 0.067 0.06 DBMET03521 | DBMET03517 | |
| 0.026 | 0.028 | 0.05 | Somatostatin agonist | 0.05 0.013 DBMET03517 0.031 0.022 DBMET03519 | DBMET03517 | |
| 0.121 | 0.125 | 0.209 | Protein kinase (CK1) gamma 3 inhibitor | 0.158 0.081 DBMET03517 0.209 0.042 DBMET03519 0.137 0.105 DBMET03520 0.16 0.079 DBMET03521 | DBMET03519 | |
| 0.058 | 0.061 | 0.068 | Prolactin release inhibitor | 0.059 0.057 DBMET03517 0.06 0.054 DBMET03519 0.059 0.057 DBMET03522 0.068 0.027 DBMET03520 0.063 0.039 DBMET03521 | DBMET03520 | |
| 0.061 | 0.065 | 0.072 | HIV-1 integrase inhibitor | 0.072 0.045 DBMET03522 | DBMET03522 | |
| 0.034 | 0.038 | 0.056 | Dopamine D5 antagonist | 0.056 0.021 DBMET03520 0.051 0.024 DBMET03521 | DBMET03520 | |
| 0.108 | 0.113 | 0.243 | Activin receptor-like kinase 2 inhibitor | 0.206 0.034 DBMET03517 0.239 0.023 DBMET03519 0.243 0.022 DBMET03520 0.225 0.027 DBMET03521 | DBMET03520 | |
| 0.053 | 0.058 | 0.076 | p38 MAP kinase inhibitor | 0.07 0.045 DBMET03519 0.076 0.042 DBMET03520 | DBMET03520 | |
| 0.014 | 0.019 | 0.025 | Kainate receptor 3 antagonist | 0.025 0.007 DBMET03522 | DBMET03522 | |
| 0.047 | 0.052 | 0.093 | Dipeptidyl peptidase inhibitor | 0.093 0.01 DBMET03517 0.06 0.026 DBMET03519 0.073 0.016 DBMET03520 0.068 0.019 DBMET03521 | DBMET03517 | |
| 0.132 | 0.138 | 0.253 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.157 0.113 DBMET03517 0.253 0.044 DBMET03519 0.177 0.096 DBMET03522 0.135 0.134 DBMET03520 | DBMET03519 | |
| 0.078 | 0.087 | 0.106 | MAP kinase 9 inhibitor | 0.106 0.058 DBMET03519 | DBMET03519 | |
| 0.094 | 0.103 | 0.217 | MAP kinase kinase inhibitor | 0.107 0.088 DBMET03517 0.217 0.023 DBMET03519 0.124 0.07 DBMET03522 0.173 0.039 DBMET03520 0.215 0.024 DBMET03521 | DBMET03519 | |
| 0.155 | 0.165 | 0.223 | DNA damaging | 0.167 0.148 DBMET03517 0.194 0.121 DBMET03519 0.168 0.147 DBMET03522 0.19 0.124 DBMET03520 0.223 0.098 DBMET03521 | DBMET03521 | |
| 0.014 | 0.025 | 0.05 | Kainate receptor 5 antagonist | 0.024 0.012 DBMET03517 0.019 0.016 DBMET03519 0.05 0.005 DBMET03522 | DBMET03522 | |
| 0.056 | 0.068 | 0.06 | Beta 3 adrenoreceptor antagonist | 0.06 0.057 DBMET03522 | DBMET03522 | |
| 0.033 | 0.046 | 0.104 | AMPA 4 receptor antagonist | 0.038 0.031 DBMET03517 0.037 0.032 DBMET03519 0.104 0.005 DBMET03522 0.037 0.032 DBMET03520 | DBMET03522 | |
| 0.044 | 0.057 | 0.056 | 5 Hydroxytryptamine 1B agonist | 0.049 0.045 DBMET03519 0.056 0.032 DBMET03520 0.049 0.045 DBMET03521 | DBMET03520 | |
| 0.079 | 0.095 | 0.116 | Cyclin-dependent kinase 9 inhibitor | 0.109 0.053 DBMET03517 0.116 0.048 DBMET03519 | DBMET03519 | |
| 0.101 | 0.118 | 0.23 | Histone deacetylase SIRT1 inhibitor | 0.119 0.092 DBMET03517 0.23 0.022 DBMET03519 0.132 0.078 DBMET03522 0.175 0.043 DBMET03520 0.186 0.036 DBMET03521 | DBMET03519 | |
| 0.039 | 0.056 | 0.056 | Benzodiazepine inverse agonist | 0.045 0.036 DBMET03519 0.056 0.018 DBMET03520 | DBMET03520 | |
| 0.244 | 0.261 | 0.273 | Caspase 9 stimulant | 0.256 0.246 DBMET03522 0.273 0.225 DBMET03521 | DBMET03521 | |
| 0.062 | 0.08 | 0.073 | Somatostatin 1 agonist | 0.073 0.06 DBMET03517 | DBMET03517 | |
| 0.022 | 0.04 | 0.084 | HCV NS5B polymerase inhibitor | 0.084 0.005 DBMET03522 0.029 0.024 DBMET03521 | DBMET03522 | |
| 0.009 | 0.028 | 0.014 | Somatostatin 2 agonist | 0.014 0.01 DBMET03517 | DBMET03517 | |
| 0.043 | 0.062 | 0.066 | Bromodomain-containing protein 4 inhibitor | 0.066 0.027 DBMET03520 0.05 0.046 DBMET03521 | DBMET03520 | |
| 0.062 | 0.084 | 0.077 | Phosphodiesterase VI inhibitor | 0.068 0.067 DBMET03522 0.077 0.046 DBMET03520 | DBMET03520 | |
| 0.076 | 0.1 | 0.167 | MAP kinase kinase 1 inhibitor | 0.091 0.069 DBMET03517 0.156 0.014 DBMET03519 0.106 0.05 DBMET03522 0.14 0.021 DBMET03520 0.167 0.011 DBMET03521 | DBMET03521 | |
| 0.038 | 0.063 | 0.069 | GABA A receptor antagonist | 0.049 0.042 DBMET03517 0.056 0.034 DBMET03518 0.069 0.026 DBMET03520 | DBMET03520 | |
| 0.039 | 0.065 | 0.078 | GABA receptor antagonist | 0.059 0.032 DBMET03517 0.056 0.035 DBMET03518 0.054 0.039 DBMET03522 0.078 0.022 DBMET03520 | DBMET03520 | |
| 0.013 | 0.041 | 0.053 | NMDA receptor glycine site antagonist | 0.028 0.014 DBMET03517 0.053 0.005 DBMET03522 | DBMET03522 | |
| 0.072 | 0.101 | 0.096 | Bromodomain-containing protein 2 inhibitor | 0.087 0.062 DBMET03520 0.096 0.045 DBMET03521 | DBMET03521 | |
| 0.069 | 0.099 | 0.084 | MAP kinase 7 inhibitor | 0.082 0.038 DBMET03520 0.084 0.033 DBMET03521 | DBMET03521 | |
| 0.042 | 0.075 | 0.077 | NMDA 2C receptor antagonist | 0.059 0.047 DBMET03517 0.077 0.027 DBMET03522 | DBMET03522 | |
| 0.084 | 0.119 | 0.101 | Nav1.5 sodium channel blocker | 0.101 0.082 DBMET03520 | DBMET03520 | |
| 0.107 | 0.143 | 0.192 | Cyclin-dependent kinase 8 inhibitor | 0.182 0.05 DBMET03519 0.137 0.094 DBMET03520 0.192 0.041 DBMET03521 | DBMET03521 | |
| 0.015 | 0.052 | 0.035 | 5 Hydroxytryptamine 1F agonist | 0.035 0.009 DBMET03520 0.023 0.021 DBMET03521 | DBMET03520 | |
| 0.029 | 0.067 | 0.056 | Phenylethanolamine N methyltransferase inhibitor | 0.056 0.01 DBMET03517 | DBMET03517 | |
| 0.021 | 0.06 | 0.142 | Kainate receptor antagonist | 0.051 0.021 DBMET03517 0.142 0.005 DBMET03522 | DBMET03522 | |
| 0.024 | 0.063 | 0.057 | Vascular adhesion protein 1 inhibitor | 0.057 0.011 DBMET03517 0.037 0.029 DBMET03520 | DBMET03517 | |
| 0.085 | 0.125 | 0.103 | CDK3/cyclin E inhibitor | 0.103 0.083 DBMET03519 | DBMET03519 | |
| 0.048 | 0.091 | 0.081 | Rho-associated kinase inhibitor | 0.081 0.046 DBMET03517 | DBMET03517 | |
| 0.02 | 0.064 | 0.047 | NMDA receptor subunit 3A antagonist | 0.047 0.021 DBMET03522 | DBMET03522 | |
| 0.108 | 0.156 | 0.209 | LIM domain kinase 1 inhibitor | 0.133 0.117 DBMET03517 0.209 0.059 DBMET03519 0.173 0.078 DBMET03521 | DBMET03519 | |
| 0.025 | 0.073 | 0.047 | MAP3K5 inhibitor | 0.047 0.015 DBMET03519 0.042 0.023 DBMET03521 | DBMET03519 | |
| 0.022 | 0.071 | 0.06 | GHS receptor antagonist | 0.06 0.005 DBMET03518 | DBMET03518 | |
| 0.035 | 0.085 | 0.061 | Dopamine D3 antagonist | 0.061 0.044 DBMET03520 | DBMET03520 | |
| 0.054 | 0.104 | 0.086 | ALK inhibitor | 0.075 0.067 DBMET03519 0.086 0.052 DBMET03520 | DBMET03520 | |
| 0.03 | 0.079 | 0.057 | Glutamate (mGluR5) agonist | 0.049 0.027 DBMET03519 0.053 0.022 DBMET03520 0.057 0.019 DBMET03521 | DBMET03521 | |
| 0.129 | 0.179 | 0.16 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.151 0.132 DBMET03517 0.16 0.119 DBMET03519 0.151 0.132 DBMET03521 | DBMET03519 | |
| 0.164 | 0.214 | 0.232 | Nootropic | 0.192 0.169 DBMET03520 0.232 0.124 DBMET03521 | DBMET03521 | |
| 0.034 | 0.084 | 0.055 | Dipeptidyl peptidase IV inhibitor | 0.055 0.015 DBMET03517 0.048 0.024 DBMET03520 0.044 0.031 DBMET03521 | DBMET03517 | |
| 0.074 | 0.124 | 0.164 | AMP-activated protein kinase stimulant | 0.115 0.054 DBMET03517 0.104 0.065 DBMET03519 0.164 0.02 DBMET03522 0.094 0.078 DBMET03520 | DBMET03522 | |
| 0.045 | 0.096 | 0.063 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.057 0.049 DBMET03517 0.056 0.052 DBMET03520 0.063 0.037 DBMET03521 | DBMET03521 | |
| 0.069 | 0.12 | 0.088 | Hematopoietic | 0.084 0.063 DBMET03517 0.087 0.055 DBMET03520 0.088 0.053 DBMET03521 | DBMET03521 | |
| 0.035 | 0.088 | 0.113 | Lysine-specific demethylase 1A inhibitor | 0.05 0.044 DBMET03517 0.052 0.042 DBMET03520 0.113 0.005 DBMET03521 | DBMET03521 | |
| 0.085 | 0.14 | 0.123 | Sodium channel blocker | 0.107 0.101 DBMET03519 0.123 0.08 DBMET03520 0.123 0.08 DBMET03521 | DBMET03521 | |
| 0.092 | 0.148 | 0.143 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | 0.137 0.087 DBMET03517 0.143 0.08 DBMET03519 | DBMET03519 | |
| 0.07 | 0.126 | 0.113 | Aurora-B kinase inhibitor | 0.113 0.07 DBMET03519 | DBMET03519 | |
| 0.004 | 0.063 | 0.016 | Thrombopoietin agonist | 0.016 0.005 DBMET03522 | DBMET03522 | |
| 0.023 | 0.082 | 0.031 | Transforming growth factor beta 2 antagonist | 0.031 0.029 DBMET03519 | DBMET03519 | |
| 0.083 | 0.142 | 0.137 | Sodium channel (voltage-gated) blocker | 0.113 0.093 DBMET03519 0.123 0.081 DBMET03520 0.137 0.065 DBMET03521 | DBMET03521 | |
| 0.005 | 0.064 | 0.092 | Kainate receptor 1 antagonist | 0.021 0.015 DBMET03517 0.092 0.004 DBMET03522 | DBMET03522 | |
| 0.029 | 0.092 | 0.058 | GABA B receptor antagonist | 0.058 0.013 DBMET03517 0.053 0.017 DBMET03522 0.049 0.02 DBMET03520 | DBMET03517 | |
| 0.055 | 0.118 | 0.093 | Opioid kappa receptor antagonist | 0.078 0.062 DBMET03519 0.093 0.042 DBMET03520 | DBMET03520 | |
| 0.101 | 0.165 | 0.195 | Polo-like kinase-3 inhibitor | 0.195 0.048 DBMET03519 0.149 0.085 DBMET03520 0.181 0.057 DBMET03521 | DBMET03519 | |
| 0.181 | 0.245 | 0.23 | Calcium channel activator | 0.222 0.182 DBMET03517 0.23 0.172 DBMET03522 | DBMET03522 | |
| 0.02 | 0.085 | 0.059 | RNA-directed RNA polymerase inhibitor | 0.059 0.01 DBMET03522 | DBMET03522 | |
| 0.041 | 0.11 | 0.07 | Nav1.7 sodium channel blocker | 0.07 0.043 DBMET03521 | DBMET03521 | |
| 0.041 | 0.112 | 0.094 | Polo-like kinase-2 inhibitor | 0.082 0.042 DBMET03519 0.08 0.044 DBMET03520 0.094 0.031 DBMET03521 | DBMET03521 | |
| 0.091 | 0.163 | 0.133 | Neurotrophic factor | 0.127 0.085 DBMET03522 0.133 0.077 DBMET03521 | DBMET03521 | |
| 0.027 | 0.102 | 0.083 | Bruton tyrosine kinase inhibitor | 0.078 0.021 DBMET03519 0.083 0.019 DBMET03520 0.066 0.029 DBMET03521 | DBMET03520 | |
| 0.111 | 0.193 | 0.143 | 3C-like protease (Human coronavirus) inhibitor | 0.139 0.122 DBMET03517 0.138 0.124 DBMET03519 0.143 0.114 DBMET03522 | DBMET03522 | |
| 0.037 | 0.122 | 0.056 | NMDA receptor agonist | 0.056 0.053 DBMET03522 | DBMET03522 | |
| 0.103 | 0.19 | 0.156 | Antimitotic | 0.155 0.117 DBMET03519 0.156 0.116 DBMET03520 | DBMET03520 | |
| 0.038 | 0.127 | 0.08 | I kappa B kinase 2 inhibitor | 0.064 0.041 DBMET03517 0.08 0.022 DBMET03519 | DBMET03519 | |
| 0.073 | 0.164 | 0.123 | Photosensitizer | 0.123 0.053 DBMET03522 | DBMET03522 | |
| 0.029 | 0.121 | 0.06 | CXC chemokine 4 receptor antagonist | 0.06 0.042 DBMET03517 | DBMET03517 | |
| 0.058 | 0.151 | 0.094 | MAP kinase kinase 7 inhibitor | 0.081 0.043 DBMET03517 0.094 0.019 DBMET03519 0.078 0.052 DBMET03522 0.075 0.061 DBMET03520 | DBMET03519 | |
| 0.013 | 0.108 | 0.061 | TRPM8 blocker | 0.061 0.011 DBMET03522 | DBMET03522 | |
| 0.141 | 0.237 | 0.215 | Transcription factor NF kappa B inhibitor | 0.215 0.155 DBMET03522 | DBMET03522 | |
| 0.009 | 0.109 | 0.062 | Plasma kallikrein inhibitor | 0.062 0.008 DBMET03517 | DBMET03517 | |
| 0.162 | 0.261 | 0.444 | Histamine release inhibitor | 0.444 0.053 DBMET03522 | DBMET03522 | |
| 0.026 | 0.131 | 0.045 | DNA gyrase subunit A inhibitor | 0.043 0.027 DBMET03517 0.045 0.024 DBMET03522 | DBMET03522 | |
| 0.055 | 0.161 | 0.276 | Ferrochelatase inhibitor | 0.106 0.065 DBMET03517 0.276 0.01 DBMET03522 | DBMET03522 | |
| 0.006 | 0.118 | 0.032 | Somatostatin 5 antagonist | 0.032 0.022 DBMET03522 | DBMET03522 | |
| 0.028 | 0.14 | 0.094 | 5 Hydroxytryptamine 3A antagonist | 0.091 0.022 DBMET03520 0.094 0.02 DBMET03521 | DBMET03521 | |
| 0.032 | 0.144 | 0.044 | Phosphodiesterase 6C inhibitor | 0.044 0.041 DBMET03520 | DBMET03520 | |
| 0.078 | 0.19 | 0.165 | Angiogenesis stimulant | 0.161 0.116 DBMET03517 0.165 0.113 DBMET03522 | DBMET03522 | |
| 0.035 | 0.151 | 0.074 | Heat shock protein 90 beta antagonist | 0.062 0.036 DBMET03519 0.074 0.025 DBMET03521 | DBMET03521 | |
| 0.039 | 0.16 | 0.072 | I kappa B kinase 1 inhibitor | 0.072 0.046 DBMET03519 | DBMET03519 | |
| 0.021 | 0.148 | 0.04 | GHS receptor agonist | 0.04 0.035 DBMET03518 | DBMET03518 | |
| 0.014 | 0.142 | 0.05 | Tryptase inhibitor | 0.05 0.012 DBMET03517 | DBMET03517 | |
| 0.158 | 0.286 | 0.344 | Antibacterial | 0.344 0.105 DBMET03518 0.308 0.129 DBMET03522 | DBMET03518 | |
| 0.095 | 0.228 | 0.151 | Antiamyloidogenic | 0.151 0.147 DBMET03522 | DBMET03522 | |
| 0.049 | 0.183 | 0.072 | GABA B receptor agonist | 0.072 0.061 DBMET03517 | DBMET03517 | |
| 0.058 | 0.192 | 0.224 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.224 0.043 DBMET03519 | DBMET03519 | |
| 0.032 | 0.169 | 0.064 | Sirtuin 1 inhibitor | 0.064 0.052 DBMET03519 | DBMET03519 | |
| 0.072 | 0.21 | 0.153 | Anticoagulant | 0.153 0.078 DBMET03517 | DBMET03517 | |
| 0.019 | 0.157 | 0.066 | Kallikrein inhibitor | 0.066 0.02 DBMET03517 | DBMET03517 | |
| 0.027 | 0.167 | 0.107 | Glutamate receptor agonist | 0.084 0.049 DBMET03519 0.091 0.044 DBMET03522 0.107 0.033 DBMET03520 0.082 0.051 DBMET03521 | DBMET03520 | |
| 0.061 | 0.201 | 0.1 | Activin receptor-like kinase 4 inhibitor | 0.1 0.085 DBMET03519 | DBMET03519 | |
| 0.015 | 0.156 | 0.041 | Factor XIa inhibitor | 0.041 0.028 DBMET03517 0.037 0.033 DBMET03522 | DBMET03517 | |
| 0.018 | 0.161 | 0.071 | Plasminogen activator inhibitor | 0.071 0.032 DBMET03517 | DBMET03517 | |
| 0.044 | 0.191 | 0.091 | MAP kinase 8 inhibitor | 0.091 0.071 DBMET03519 | DBMET03519 | |
| 0.059 | 0.205 | 0.131 | Tyrosine kinase inhibitor | 0.126 0.104 DBMET03519 0.131 0.101 DBMET03520 | DBMET03520 | |
| 0.037 | 0.186 | 0.098 | I kappa B kinase inhibitor | 0.074 0.069 DBMET03517 0.098 0.041 DBMET03519 | DBMET03519 | |
| 0.036 | 0.187 | 0.063 | Telomerase inhibitor | 0.063 0.061 DBMET03521 | DBMET03521 | |
| 0.059 | 0.215 | 0.083 | CC chemokine 5 receptor agonist | 0.083 0.054 DBMET03518 | DBMET03518 | |
| 0.034 | 0.199 | 0.07 | Kallikrein 1 inhibitor | 0.07 0.024 DBMET03517 | DBMET03517 | |
| 0.038 | 0.206 | 0.063 | Histone deacetylase SIRT3 inhibitor | 0.063 0.04 DBMET03519 | DBMET03519 | |
| 0.081 | 0.25 | 0.177 | I kappa B kinase epsilon inhibitor | 0.177 0.092 DBMET03519 0.171 0.098 DBMET03522 0.174 0.095 DBMET03521 | DBMET03519 | |
| 0.014 | 0.185 | 0.06 | Prostaglandin antagonist | 0.06 0.032 DBMET03522 | DBMET03522 | |
| 0.019 | 0.193 | 0.052 | 5 Hydroxytryptamine 3 antagonist | 0.052 0.045 DBMET03521 | DBMET03521 | |
| 0.056 | 0.231 | 0.083 | Transforming growth factor beta 3 antagonist | 0.083 0.054 DBMET03521 | DBMET03521 | |
| 0.031 | 0.209 | 0.093 | Potassium channel (Ca-activated) activator | 0.093 0.062 DBMET03522 | DBMET03522 | |
| 0.031 | 0.21 | 0.061 | Protease 3C (Human rhinovirus) inhibitor | 0.061 0.051 DBMET03519 | DBMET03519 | |
| 0.028 | 0.215 | 0.15 | Protein kinase (CK2) inhibitor | 0.15 0.033 DBMET03522 | DBMET03522 | |
| 0.036 | 0.223 | 0.082 | Carbonic anhydrase VI inhibitor | 0.082 0.055 DBMET03522 | DBMET03522 | |
| 0.033 | 0.222 | 0.127 | Alcohol dehydrogenase inhibitor | 0.127 0.03 DBMET03518 0.088 0.067 DBMET03519 0.124 0.032 DBMET03522 0.081 0.078 DBMET03520 | DBMET03518 | |
| 0.041 | 0.23 | 0.171 | GABA C receptor agonist | 0.109 0.058 DBMET03517 0.171 0.027 DBMET03522 | DBMET03522 | |
| 0.005 | 0.195 | 0.014 | Dipeptidyl peptidase VIII inhibitor | 0.014 0.012 DBMET03517 | DBMET03517 | |
| 0.031 | 0.222 | 0.067 | Glutamate (mGluR7) antagonist | 0.067 0.049 DBMET03520 0.067 0.049 DBMET03521 | DBMET03521 | |
| 0.03 | 0.221 | 0.058 | Corticotropin releasing factor 2 receptor antagonist | 0.058 0.052 DBMET03521 | DBMET03521 | |
| 0.124 | 0.32 | 0.201 | Insulysin inhibitor | 0.201 0.155 DBMET03522 | DBMET03522 | |
| 0.047 | 0.248 | 0.133 | Thrombolytic | 0.133 0.096 DBMET03522 | DBMET03522 | |
| 0.005 | 0.207 | 0.018 | Dipeptidyl peptidase IX inhibitor | 0.018 0.009 DBMET03517 | DBMET03517 | |
| 0.057 | 0.262 | 0.194 | EphB2 antagonist | 0.194 0.092 DBMET03519 | DBMET03519 | |
| 0.04 | 0.255 | 0.091 | Polo-like kinase-1 inhibitor | 0.087 0.068 DBMET03520 0.091 0.059 DBMET03521 | DBMET03521 | |
| 0.168 | 0.384 | 0.315 | Antiinflammatory | 0.315 0.202 DBMET03522 | DBMET03522 | |
| 0.135 | 0.355 | 0.236 | 5 Hydroxytryptamine uptake stimulant | 0.2 0.152 DBMET03519 0.236 0.096 DBMET03522 0.188 0.176 DBMET03520 0.219 0.119 DBMET03521 | DBMET03522 | |
| 0.093 | 0.317 | 0.21 | Superoxide dismutase inhibitor | 0.21 0.107 DBMET03522 | DBMET03522 | |
| 0.086 | 0.319 | 0.166 | Cyclic AMP phosphodiesterase inhibitor | 0.166 0.127 DBMET03522 | DBMET03522 | |
| 0.062 | 0.297 | 0.16 | Hexokinase inhibitor | 0.16 0.068 DBMET03522 | DBMET03522 | |
| 0.083 | 0.318 | 0.179 | Lipocortins synthesis antagonist | 0.179 0.072 DBMET03522 | DBMET03522 | |
| 0.021 | 0.259 | 0.047 | Glutamate (mGluR group III) antagonist | 0.047 0.025 DBMET03522 | DBMET03522 | |
| 0.007 | 0.245 | 0.027 | Nicotinic acid receptor 2 antagonist | 0.027 0.017 DBMET03522 | DBMET03522 | |
| 0.038 | 0.282 | 0.159 | Histone deacetylase class III inhibitor | 0.159 0.037 DBMET03519 0.129 0.062 DBMET03520 0.127 0.064 DBMET03521 | DBMET03519 | |
| 0.04 | 0.301 | 0.086 | Carbonic anhydrase III inhibitor | 0.086 0.08 DBMET03522 | DBMET03522 | |
| 0.021 | 0.285 | 0.137 | Protein kinase (CK2) alpha inhibitor | 0.137 0.05 DBMET03522 | DBMET03522 | |
| 0.002 | 0.27 | 0.011 | Retinoic acid beta receptor antagonist | 0.011 0.01 DBMET03522 | DBMET03522 | |
| 0.066 | 0.336 | 0.168 | Non-steroidal antiinflammatory agent | 0.168 0.097 DBMET03522 | DBMET03522 | |
| 0.012 | 0.296 | 0.06 | Dihydroorotase inhibitor | 0.06 0.016 DBMET03522 | DBMET03522 | |
| 0.075 | 0.362 | 0.16 | Sphingosine 1-phosphate receptor 5 antagonist | 0.128 0.105 DBMET03517 0.132 0.095 DBMET03519 0.16 0.046 DBMET03522 0.133 0.093 DBMET03520 | DBMET03522 | |
| 0.016 | 0.316 | 0.09 | Lipase inhibitor | 0.09 0.033 DBMET03518 | DBMET03518 | |
| 0.059 | 0.362 | 0.126 | Hemostatic | 0.126 0.103 DBMET03517 | DBMET03517 | |
| 0.01 | 0.321 | 0.057 | Dihydroorotate dehydrogenase inhibitor | 0.057 0.03 DBMET03522 | DBMET03522 | |
| 0.051 | 0.366 | 0.182 | Platelet antagonist | 0.182 0.116 DBMET03522 | DBMET03522 | |
| 0.026 | 0.345 | 0.111 | Creatine kinase inhibitor | 0.111 0.049 DBMET03522 | DBMET03522 | |
| 0.012 | 0.343 | 0.098 | Histone deacetylase SIRT2 inhibitor | 0.098 0.031 DBMET03519 0.069 0.056 DBMET03520 0.069 0.056 DBMET03521 | DBMET03519 | |
| 0.018 | 0.369 | 0.056 | Prostaglandin F2 alpha antagonist | 0.056 0.054 DBMET03522 | DBMET03522 | |
| 0.026 | 0.379 | 0.09 | Keratolytic | 0.09 0.038 DBMET03522 | DBMET03522 | |
| 0.09 | 0.45 | 0.137 | Ca2+-transporting ATPase inhibitor | 0.137 0.087 DBMET03522 | DBMET03522 | |
| 0.049 | 0.413 | 0.117 | Insulin secretagoues | 0.117 0.116 DBMET03522 | DBMET03522 | |
| 0.029 | 0.403 | 0.099 | Triose-phosphate isomerase inhibitor | 0.099 0.049 DBMET03522 | DBMET03522 | |
| 0.029 | 0.404 | 0.152 | Alpha-N-acetylglucosaminidase inhibitor | 0.152 0.054 DBMET03522 | DBMET03522 | |
| 0.11 | 0.5 | 0.351 | 5 Hydroxytryptamine release inhibitor | 0.294 0.171 DBMET03519 0.351 0.114 DBMET03522 | DBMET03522 | |
| 0.006 | 0.395 | 0.039 | Nicotinic acid receptor 2 agonist | 0.039 0.021 DBMET03522 | DBMET03522 | |
| 0.004 | 0.395 | 0.017 | Retinoic acid receptor antagonist | 0.017 0.015 DBMET03522 | DBMET03522 | |
| 0.01 | 0.434 | 0.073 | Porphobilinogen synthase inhibitor | 0.073 0.053 DBMET03522 | DBMET03522 | |
| 0.027 | 0.453 | 0.096 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.096 0.058 DBMET03522 | DBMET03522 | |
| 0.027 | 0.455 | 0.086 | Electrolyte absorption antagonist | 0.086 0.081 DBMET03522 | DBMET03522 | |
| 0.021 | 0.451 | 0.084 | UDP-glucose 4-epimerase inhibitor | 0.084 0.083 DBMET03522 | DBMET03522 | |
| 0.007 | 0.442 | 0.031 | Purinergic P2Y14 antagonist | 0.031 0.02 DBMET03522 | DBMET03522 | |
| 0.008 | 0.444 | 0.049 | Retinoic acid alpha receptor agonist | 0.049 0.015 DBMET03522 | DBMET03522 | |
| 0.013 | 0.452 | 0.053 | Aggrecanase 1 inhibitor | 0.053 0.012 DBMET03518 | DBMET03518 | |
| 0.086 | 0.557 | 0.223 | Interleukin 2 agonist | 0.223 0.152 DBMET03520 | DBMET03520 | |
| 0.006 | 0.494 | 0.026 | NMDA 2D receptor antagonist | 0.026 0.021 DBMET03522 | DBMET03522 | |
| 0.069 | 0.57 | 0.286 | Cyclophilin D inhibitor | 0.286 0.176 DBMET03522 | DBMET03522 | |
| 0.019 | 0.63 | 0.053 | Adenine nucleotide translocase inhibitor | 0.053 0.047 DBMET03522 | DBMET03522 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |